TrovaGene Company Profile (NASDAQ:TROV)

About TrovaGene

TrovaGene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TROV
  • CUSIP:
Key Metrics:
  • Previous Close: $2.10
  • 50 Day Moving Average: $2.16
  • 200 Day Moving Average: $3.49
  • 52-Week Range: $1.77 - $6.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.02
  • P/E Growth: 0.00
  • Market Cap: $62.76M
  • Outstanding Shares: 30,615,000
  • Beta: 0.8
  • Net Margins: -9,703.32%
  • Return on Equity: -104.43%
  • Return on Assets: -63.04%
  • Debt-to-Equity Ratio: 0.58%
  • Current Ratio: 7.31%
  • Quick Ratio: 7.31%
Additional Links:
Companies Related to TrovaGene:

Analyst Ratings

Consensus Ratings for TrovaGene (NASDAQ:TROV) (?)
Ratings Breakdown: 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $6.75 (221.43% upside)

Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
DateFirmActionRatingPrice TargetDetails
12/14/2016Cantor FitzgeraldSet Price TargetBuy$8.00View Rating Details
10/6/2016Maxim GroupReiterated RatingBuy$9.00View Rating Details
8/5/2016Piper Jaffray CompaniesSet Price TargetHold$5.00 -> $4.00View Rating Details
5/12/2016Leerink SwannReiterated RatingHoldView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00View Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
2/22/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
(Data available from 2/22/2015 forward)


Earnings History for TrovaGene (NASDAQ:TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.29)($0.36)ViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$100.00 millionViewListenView Earnings Details
8/10/2015Q215($0.24)($0.41)ViewListenView Earnings Details
5/5/2015($0.23)($0.24)ViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)ViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)ViewN/AView Earnings Details
8/11/2014($0.24)($0.18)ViewN/AView Earnings Details
5/12/2014($0.23)($0.17)ViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for TrovaGene (NASDAQ:TROV)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.04 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20162($0.33)($0.33)($0.33)
Q3 20162($0.38)($0.37)($0.38)
Q4 20161($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for TrovaGene (NASDAQ:TROV)
Insider Ownership Percentage: 10.70%
Institutional Ownership Percentage: 27.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stanley TennantDirectorBuy10,000$2.10$21,000.00View SEC Filing  
12/16/2016Stanley TennantDirectorBuy14,966$2.00$29,932.00View SEC Filing  
12/16/2016William J WelchCEOBuy4,750$2.09$9,927.50View SEC Filing  
12/14/2016Mark ErlanderInsiderBuy5,000$2.08$10,400.00View SEC Filing  
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for TrovaGene (NASDAQ:TROV)
DateHeadline logoTrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:TROV) - February 16 at 8:11 PM logoTrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:TROV) - February 16 at 8:11 PM
News IconTrovaGene, Inc. (NASDAQ:TROV) Quarterly EPS At $-0.11 - Stock Observer (NASDAQ:TROV) - February 15 at 6:36 AM logoCell-Free DNA (cfDNA) Testing Market 2016 - 2024; Quantifying market opportunities through market sizing and market forecasting (NASDAQ:TROV) - February 11 at 5:47 AM
News IconTrovaGene, Inc. (NASDAQ:TROV) Daily Sentiment Score At -0.217 - Stock Observer (NASDAQ:TROV) - February 10 at 6:11 AM logoGlobal Liquid Biopsy Market 2016-2022: Key Findings, Regional Analysis, Key Players Profiles and Future Prospects (NASDAQ:TROV) - February 9 at 6:17 AM logoLiquid Biopsy Market to Grow at a CAGR of 21.7% by 2026 End (NASDAQ:TROV) - February 6 at 10:44 PM logoSentiments And Ratings Alert: TrovaGene, Inc. (NASDAQ:TROV) - Investor Newswire (NASDAQ:TROV) - February 5 at 8:08 PM
News IconLiquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016- 2024 (NASDAQ:TROV) - February 4 at 5:28 AM
News IconGenePeeks Appoints Industry Leader Matt Posard as President and Chief Commercial Officer (NASDAQ:TROV) - February 2 at 6:09 AM
News IconAre Insiders Bumping Up Their Positions in TrovaGene, Inc. (NASDAQ:TROV) - Wall Street Beacon (NASDAQ:TROV) - January 30 at 10:53 AM
News IconLiquid Biopsy Global Market Other Key Strategies By Type & Geography Analysis & Forecast to 2022 (NASDAQ:TROV) - January 28 at 7:07 AM logoLiquid Biopsy Products Market Is Progressing Towards a Strong Growth by 2024 – Persistence Market Research Report (NASDAQ:TROV) - January 27 at 6:22 AM logoCleanSpark, Inc. (OTCMKTS:CLSK) Files An 8-K Regulation FD Disclosure (NASDAQ:TROV) - January 27 at 6:21 AM
News IconTrading Indicator Check on TrovaGene Inc. (TROV) - Sherwood Daily (NASDAQ:TROV) - January 26 at 6:24 AM
News IconBargain Hunter's Delight: What's the Latest on TrovaGene, Inc. (NASDAQ:TROV) - Prospect Journal (NASDAQ:TROV) - January 26 at 6:24 AM
News IconTrovaGene, Inc. (NASDAQ:TROV) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:TROV) - January 26 at 6:24 AM
News IconTrading Radar: Zooming in on Shares of TrovaGene Inc. (TROV) - Sherwood Daily (NASDAQ:TROV) - January 25 at 7:50 AM
News IconValue Focus: Following the Numbers for TrovaGene, Inc. (NASDAQ:TROV) - The Tribune (NASDAQ:TROV) - January 25 at 7:50 AM logoForm 8-K Trovagene, Inc. For: Jan 24 - (NASDAQ:TROV) - January 25 at 7:50 AM logoPublication of Trovera™ KRAS Liquid Biopsy Test Demonstrates Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response (NASDAQ:TROV) - January 24 at 8:57 AM logoCell-Free DNA (cfDNA) Testing Market: Increasing healthcare expenditure and rising healthcare awareness are the reasons driving the market (NASDAQ:TROV) - January 24 at 12:24 AM logoLiquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026 (NASDAQ:TROV) - January 24 at 12:24 AM logoCell-Free DNA (cfDNA) Testing Market Share, Size, Growth & Forecast 2024 Illuminated by New Report (NASDAQ:TROV) - January 21 at 4:05 AM
News IconAre Institutions Trimming Down Their Positions In TrovaGene, Inc. (NASDAQ:TROV) - Wall Street Beacon (NASDAQ:TROV) - January 20 at 7:16 AM
News IconCan This Stock Price Climb The Ladder: TrovaGene, Inc. (NASDAQ ... - Prospect Journal (NASDAQ:TROV) - January 20 at 7:16 AM logoTROVAGENE, INC. Files SEC form 8-K, Other Events (NASDAQ:TROV) - January 19 at 5:41 AM
News IconStock Perspective: TrovaGene, Inc. (NASDAQ:TROV) Earnings in View - Aiken Advocate (NASDAQ:TROV) - January 18 at 3:09 AM
News IconStock in the Limelight: TrovaGene, Inc. (NASDAQ:TROV) - Prospect Journal (NASDAQ:TROV) - January 18 at 3:09 AM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: TrovaGene, Inc. (NASDAQ:TROV) - Prospect Journal (NASDAQ:TROV) - January 17 at 10:36 AM
News IconTracking Corporate Insiders: What Are They Doing With TrovaGene, Inc. (NASDAQ:TROV) - Wall Street Beacon (NASDAQ:TROV) - January 17 at 10:36 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: TrovaGene, Inc. (NASDAQ:TROV) - Wall Street Beacon (NASDAQ:TROV) - January 15 at 2:22 AM logoCell-Free DNA (cfDNA) Testing Market Global Research Report 2017 Analysis and Forecast to 2021 (NASDAQ:TROV) - January 14 at 6:39 AM logoTrovagene Announces Broadening Network of Commercial Distributors (NASDAQ:TROV) - January 14 at 6:39 AM
News IconAre Institutions Jumping Ship on TrovaGene, Inc. (NASDAQ:TROV) - Wall Street Beacon (NASDAQ:TROV) - January 13 at 2:09 AM
News IconIs This Equity Ready for a Breakout: TrovaGene, Inc. (NASDAQ:TROV) - Prospect Journal (NASDAQ:TROV) - January 13 at 2:09 AM
News IconWill The Needle Move For TrovaGene, Inc. (NASDAQ:TROV) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:TROV) - January 13 at 2:09 AM logoForm 8-K Trovagene, Inc. For: Jan 12 - (NASDAQ:TROV) - January 13 at 2:09 AM logoTrovagene,Inc. (NASDAQ:TROV) Files An 8-K Other Events - Market Exclusive (NASDAQ:TROV) - January 11 at 7:02 AM
News IconTrovaGene, Inc. (NASDAQ:TROV) Quarterly EPS Set At $-0.11 - Stock Observer (NASDAQ:TROV) - January 11 at 7:02 AM logoLiquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End User - Forecast to 2021 (NASDAQ:TROV) - January 10 at 2:44 AM logoGlobal Liquid Biopsy Market is Estimated to Grow at a CAGR over 21.6% by 2022 (NASDAQ:TROV) - January 9 at 3:06 AM logoForm 4/A Trovagene, Inc. For: Jan 02 Filed by: Markin Rodney S - (NASDAQ:TROV) - January 7 at 6:07 AM
News IconBearish Target Of TrovaGene, Inc. (NASDAQ:TROV) At $9 - Stock Observer (NASDAQ:TROV) - January 7 at 6:07 AM
News IconAre There Any Catalysts to Propel Shares of TrovaGene, Inc ... - Prospect Journal (NASDAQ:TROV) - January 5 at 7:12 AM
News IconDaily Sentiment Score Of TrovaGene, Inc. (NASDAQ:TROV) At 0 - Stock Observer (NASDAQ:TROV) - January 5 at 7:12 AM logoCell-Free DNA (Cfdna) Testing Market : A Booming Trend In Healthcare Analytics Industry, Advanced Technologies & Forecast 2016 – 2024 (NASDAQ:TROV) - December 28 at 8:44 AM
News IconTrovaGene, Inc. (NASDAQ:TROV) Bearish Target At $9 - Stock Observer (NASDAQ:TROV) - December 23 at 9:55 PM
News IconShares in Review: TrovaGene, Inc. (NASDAQ:TROV) - Liberty News (NASDAQ:TROV) - December 22 at 5:09 AM
News IconIs the Needle Ready to Move on TrovaGene, Inc. (NASDAQ:TROV) - Prospect Journal (NASDAQ:TROV) - December 20 at 9:39 PM


What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?

8 equities research analysts have issued 1-year price objectives for TrovaGene's stock. Their predictions range from $4.00 to $9.00. On average, they expect TrovaGene's stock price to reach $6.75 in the next twelve months.

When will TrovaGene announce their earnings?

TrovaGene is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:

  • According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (12/7/2016)

  • Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)

  • Maxim Group analysts commented, "Trovagene announced that the company has entered into an agreement with Multiplan, Inc." (3/1/2016)

Who owns TrovaGene stock?

TrovaGene's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (1.41%). Company insiders that own TrovaGene stock include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch.

Who bought TrovaGene stock? Who is buying TrovaGene stock?

TrovaGene's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought TrovaGene stock in the last two years include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch.

How do I buy TrovaGene stock?

Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TrovaGene stock cost?

One share of TrovaGene stock can currently be purchased for approximately $2.10.

TrovaGene (NASDAQ:TROV) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)

Earnings History Chart

Earnings by Quarter for TrovaGene (NASDAQ:TROV)

Dividend History Chart

Dividend Payments by Quarter for TrovaGene (NASDAQ:TROV)

Last Updated on 2/22/2017 by Staff